Tidal Investments LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 52.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 15,043 shares of the company's stock after acquiring an additional 5,197 shares during the period. Tidal Investments LLC's holdings in Neurocrine Biosciences were worth $1,733,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences during the 2nd quarter valued at $30,000. EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth $35,000. Blue Trust Inc. grew its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd increased its holdings in shares of Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company's stock valued at $59,000 after purchasing an additional 130 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on NBIX shares. William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Monday. BMO Capital Markets decreased their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research note on Thursday, October 17th. Raymond James reaffirmed an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Piper Sandler raised shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and upped their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $165.00.
Read Our Latest Stock Report on NBIX
Insider Transactions at Neurocrine Biosciences
In other news, insider Jude Onyia sold 2,331 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now owns 15,449 shares of the company's stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.
Neurocrine Biosciences Price Performance
Shares of Neurocrine Biosciences stock traded down $1.24 during trading on Wednesday, hitting $135.45. 2,132,949 shares of the company's stock traded hands, compared to its average volume of 878,025. The company has a market cap of $13.71 billion, a PE ratio of 36.31 and a beta of 0.34. The firm's fifty day moving average price is $122.66 and its 200 day moving average price is $130.57. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98.
About Neurocrine Biosciences
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
